Duty to Warn Despite this knowledge, plaintiffs allege: Warnings about gastroparesis were inadequate The permanence of stomach paralysis was understated Patients were not informed it could be irreversible Marketing emphasized weight loss benefits without balancing risks 3
Despite the valuable insights gained from this scoping review, several limitations should be acknowledged
OZEMPIC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
See Part 3 for an exploration of the many exciting possibilities that incretin-based therapies may yet unlock
A patient may be a candidate for GLP-1 weight loss if they have obesity, overweight with weight-related health concerns, insulin resistance, prediabetes, type 2 diabetes risk, high blood pressure, high cholesterol, fatty liver concerns, sleep apnea risk, or repeated difficulty losing and maintaining weight with lifestyle changes alone
If you experience abdominal pain that radiates to the back, with or without nausea, seek immediate medical attention, as this is a potential sign of pancreatitis, which is a rare but serious adverse event associated with GLP-1 class medications
00226-8/asset/34cd96f1-6db7-4717-834c-4ef722d58de8/main.assets/gr3_lrg.jpg)
